Purpose Toxoplasmosis, caused by the parasite Toxoplasma gondii, can have serious impacts on fetal development in the setting of acute maternal primary infection. The American College of Obstetricians and Gynecologists (ACOG) sought to determine current knowledge, practices, opinions, and educational preferences regarding T. gondii infection in pregnancy among ACOG members practicing prenatal care. Methods ACOG sent a survey to 1,056 members chosen by stratified random sampling from membership lists, including 370 participants and 686 non-participants in the Collaborative Ambulatory Research Network (CARN). Mailings were sent up to four times to nonresponders.
Introduction
Acute Toxoplasma gondii infection in pregnant women can cause serious sequelae in their infants. If transplacental transmission causes fetal infection, neurologic and ocular birth defects can result. However, with early maternal diagnosis, treatment regimens are available that may decrease risk of transplacental transmission, or reduce clinical manifestations if transmission occurs. Due to the lack of well-controlled studies, though, the efficacy of these treatments and the utility of routine screening remain controversial. In the United States there are no universally accepted guidelines, and practice varies.
The American College of Obstetricians and Gynecologists (ACOG) conducted surveys of obstetrical providers in 1998 [1] and 2006 [2] . These identified educational needs later addressed in an ACOG practice bulletin [3] . In 2012, we circulated a third updated survey to the ACOG membership to follow changes in practitioner knowledge, practices, and opinions. Here we report results.
Materials and methods
A questionnaire was developed with reference to the prior surveys, and pilot-tested by ACOG. It addressed experience, knowledge and practices regarding screening, diagnosis and management of acute maternal and fetal toxoplasmosis; and opinions on legislative regulation of screening and continuing education needs. Demographic characteristics, practice type and patient population were also collected. Participants were selected from among ACOG members, including both non-participants and participants in ACOG's Collaborative Ambulatory Research Network (CARN), a cadre of practicing obstetrician-gynecologists who have agreed to participate in periodic ACOG surveys.
Stratified random sampling was used to sort ACOG and CARN members into groups of 100, balanced on age, gender and geography, minus losses due to invalid addresses or discontinued practice. Then groups were randomly selected to total a similar target respondent number to previous ACOG surveys. In 2012-2013, the questionnaire was mailed (including four mailings to nonresponders) to 1,056 ACOG members (370 CARN members, 686 non-CARN). Analysis was performed using SAS Enterprise Guide version 9.3 (SAS Institute, Cary, NC). Respondent surveys were included if their CARN affiliation was known, they answered more than three survey questions, and they were currently practicing obstetrics including prenatal care. US Census regions [4] were used to delineate practice regions.
Responses were analyzed separately for CARN and non-CARN respondents. Denominators vary because not all respondents answered all questions. Results are for the total proportion of respondents selecting a given answer; therefore, for questions accepting multiple answers, totals may exceed 100 %. Answer proportions were compared between groups using the Fisher's exact test for categorical variables and a two-sample t test for continuous variables. If not significantly different, groups were pooled to calculate total proportions giving each answer, for which 95 % Clopper-Pearson confidence intervals (CIs) were calculated; otherwise, proportions were calculated for each group separately.
Univariate Poisson regression models were used to investigate the association between selected outcome variables-ever performing serologic screening on pregnant women, correctly identifying letting a pet cat go outdoors and gardening as risk factors, and using an ''acceptable'' 1 seroscreening method-and covariates including provider gender, years elapsed since completing residency, primary practice field, and geographic region. If more than one covariate was associated with a given outcome, multivariate Poisson regression using all covariates significant at alpha = 0.05 on univariate analysis (forward stepwise approach) was performed for that outcome. P values are provided, allowing assessment of significance at either p \ 0.05, or p \ 0.0125 after adjusting for multiple comparisons.
The study was reviewed and exempted by ACOG and CDC human subjects committees.
Results

Response rate
The participant flowchart, including response rates, is in Fig. 1 . The minimum response rates were as follows: 40.3 % CARN, 19.7 % non-CARN; if nonrespondents were ineligible in the same proportion as respondents, however, response rates were 59.7 % CARN and 22.6 % non-CARN.
Respondent demographics
Respondents had been practicing for a mean of 21.0 years. Mean age was 52.7 years in 2012 (95 % CI 51.6-53.1); mean years in practice were 21.0 (95 % CI 19.8-22.0). Other characteristics are in Table 1 . Only in gender were CARN and non-CARN respondents different (p = 0.04; CARN percent male = 41.9 %, 95 % CI 34.1-50.1 %; non-CARN, 50.8 %, 95 % CI 41.5-60.2 %).
Other significant differences between CARN and non-CARN respondents were uncommon and are noted below. Among those who identified gardening without gloves as a risk factor, CARN and non-CARN providers were significantly (p = 0.04) more likely to include it in counseling.
Overall, 6.4 % of providers answered 4 or fewer risk factor questions correctly, 40.1 % 5-8, 47.9 % 9-12, and 5.6 % more than 12. Among providers answering nine or more questions correctly, often-missed risk factors were eating raw or undercooked oysters, mussels or clams (35.8 %); eating unwashed raw fruits or vegetables (55.0 %); and drinking untreated water from a stream, lake or pond (55.0 %).
Screening and diagnosis
Forty-two and six tenths percent of providers (95 % CI 36.7-48.6 %) reported ever seroscreening for acute T. gondii infection in asymptomatic pregnant women. Of these, 55.6 % reported deciding who to screen by asking about risk factors; 27.8 % also required absence of a previous positive serology. Respondents who seroscreened generally did so once, either as early as possible (70. gondii titer'', a term interpretable as referring to tests which do not discriminate between IgG and IgM); 2.3 % (95 % CI 0.5-6.5 %) IgM only (with or without ''T. gondii titer''), 7.6 % (95 % CI 3.7-13.5 %) ''T. gondii titer'' only, 0.8 % (95 % CI 0.0-4.2 %) IgA, and 6.1 % (2.7-11.6 %) did not know.
Among approaches to confirmation, most common were answers containing both IgG and IgM (20.8 %), T. gondii titer only (8.0 %), and 'don't know' (24.6 %); 46.6 % took other approaches. Toxoplasma avidity was included by 9.7 %. Eleven and one tenth percent of respondents would send confirmatory testing (vs. 1.9 % initial testing) to the Palo Alto Research Institute's Toxoplasma Serology Laboratory, a nonprofit institution offering expert testing.
Approach to acute maternal and fetal T. gondii infection Given a diagnosis of acute maternal T. gondii infection at 14 or 23 weeks' gestation, most providers (92.0 and 93.6 %, respectively) would consult a specialist. Fewer would begin antimicrobial therapy (14.4 and 8.6 %, respectively) or perform amniocentesis (7.6 and 9.5 %, respectively). For fetal toxoplasmosis, 84.4 % would consult with an infectious disease specialist, 11 % begin antimicrobial treatment, 10.3 % perform immediate fetal ultrasound, and 0.8 % recommend termination. In the case of acute maternal infection at 14 weeks, CARN respondents were significantly more likely (p = 0.01) to begin antimicrobial therapy than non-CARN respondents.
Provider knowledge about toxoplasmosis testing options Most respondents were not sure which screening test gives frequent false positives (62.1 %; IgM is correct) or false negatives (70.9 %; no widely used test is correct). Only 7.2 % correctly stated that the effectiveness of spiramycin against maternal-fetal T. gondii transmission is unknown or controversial (51.3 % did not know), and 12.7 % that the Toxoplasma avidity test determines whether maternal T. gondii infection occurred in the last 3-4 months. CARN members were significantly more likely (p = 0.03) to answer this question correctly than non-CARN members.
Provider opinions on standardized screening approaches Eighty-nine percent of respondents were opposed (1 or 2 on a 5-point scale) to universal monthly toxoplasmosis screening in pregnancy, 72 % to universal screening once For the scenario of state-mandated universal monthly screening, often-cited benefits were improved patient knowledge about and avoidance of exposure to T. gondii risk factors (40.8 %) and identification of toxoplasmosis infections without known risk factors (40.5 %). Often-cited disadvantages were false-positive results leading to unnecessary workup and/or treatment with potential side effects (72.6 %) or unnecessary anxiety (65.8 %), and lack of evidence of cost-effectiveness (70.7 %).
Provider sources of information
The most-cited sources of information on advances in obstetrics and gynecology infectious disease care used by respondents were ACOG publications (37.9 % first choice; 82.8 % among top 3 choices), followed by journals (24.1 %; 53.1 %) and UpToDate (14.6 %; 43.4 %); 53.4 % also listed CME activities with any ranking. Sources favored by respondents (first, second or third choice) for ACOG to help physicians develop the skills to manage acute toxoplasmosis in pregnancy were updating ACOG guidelines on screening and management (81.4 and 71.7 %, respectively), feature articles in newsletters (30.1 %), CME monographs (26.4 %), and online CME (20.3 %).
Comparison with prior years
Ninety and four tenths percent of the 1998 respondents had diagnosed no acute cases of toxoplasmosis in the past year, 
Associative analysis
Providers in the Northeast were 2.02 times (95 % CI 1.31-3.72; p = 0.025) more likely than those in the West to ever screen for acute maternal toxoplasmosis in asymptomatic pregnant women (59.1 vs. 29.3 %). Female providers were 1.48 times (95 % CI 1.00-2.17; p = 0.047) more likely to do so than male providers (63.1 vs. 42.6 %). With both covariates included, region remained significant (1.98; 95 % CI 1.30-3.67; p = 0.028); gender did not (1.45; 95 % CI 0.98-2.15; p = 0.062). Other associations were not significant.
Discussion
Fetal toxoplasmosis is an uncommon but potentially serious complication of pregnancy. An estimated 89 % of women of childbearing age are susceptible to acute T. gondii infection (not previously infected) [5] , with roughly 400-4,000 [6] [7] [8] [9] newborns born with congenital T. gondii infection annually in the United States. An increasing majority of obstetricians counsel pregnant women about risk factors for toxoplasmosis. While exposures from cat litter, sandboxes and raw meat were well recognized, other risk factors for transmission via domestic cats, gardening, travel without food and water precautions, and soil exposure were less recognized. This is important given the importance of outdoor exposure of domestic cats [10] , soil exposure [11] and travel [12] as risk factors for infection. Awareness of the Toxoplasma avidity test remains uncommon. Availability of comparison over time was limited by the substantial changes in the 2012 survey compared to prior years, but practitioner knowledge about toxoplasmosis does not appear to have increased substantially.
Changing cat litter daily can virtually eliminate the potential for T. gondii transmission by this mode, as oocysts require 1-5 days to become infectious [13, 14] . T. gondii from infected feces can survive in soil for over a year [15] and contaminate hands, fruits or vegetables, and water. Pregnant women can minimize exposure risks by eating only washed produce and when gardening, wearing gloves and washing hands afterward, including removing dirt under the nails.
Roughly half of providers sometimes seroscreened asymptomatic pregnant women, most commonly based on risk factors; the most-preferred approach among our respondents was seroscreening only for patients with risk factors or recent signs or symptoms. For diagnoses of acute maternal T. gondii infection or fetal toxoplasmosis, respondents favored specialist consultation.
No approach to toxoplasmosis screening or management is universally endorsed. One expert group in the United States, Montoya and Remington [16] , recommends screening all pregnant women for IgG and IgM early in the first trimester; 59.1 % of respondents who screened used both tests. Depending on results, this group recommends following up initial positive results by retesting (for example, when IgG-negative, IgM-positive) or sending samples to the Palo Alto Medical Foundation Toxoplasma Serology Laboratory (IgG and IgM both positive), where Toxoplasma avidity testing may be used. Eleven and one tenth percent of our survey respondents would send confirmatory testing to this laboratory.
Montoya and Remington's approach takes into account properties of the screening tests: IgM has a high falsepositive rate (reported specificities range between 49.2 % [17] and 98.6 % [17, 18] ). A true positive indicates infection within the past 12-18 months (in some cases T. gondii IgM can persist for up to 2 years [19] ) A truepositive IgG result only indicates infection at some point in the past; of questions about test characteristics, this was the only one answered correctly by most respondents.
In contrast, another expert group, Gilbert and others [20] and the Society of Obstetricians and Gynecologists of Canada (SOGC) [21] , recommend screening only in cases of high suspicion, such as suggestive maternal symptoms or high-risk exposures (consistent with the answers of 87.4 % of respondents). Several countries have considered but not adopted universal screening [22] [23] [24] [25] [26] . Reasons include both costs and such possible harms [27] as unnecessary treatment due to overdiagnosis and pregnancy terminations. Followup has also proven challenging: late initial testing and poor compliance with screening intervals have led to delayed therapy in France [28] and Austria [29] .
The Healthcare Blue Book cites $30 for physicianordered Toxoplasma IgG testing and $35 for Toxoplasma IgM as reimbursement levels typically accepted from insurers [30] -considerably lower than respondents' estimates. Awareness of the Toxoplasma avidity test remains low. Often this test can help distinguish whether infection occurred in the past 3-4 months [31, 32] , a useful feature for first-trimester diagnoses given the long persistence of IgM.
Most providers indicated they would seek expert help after diagnosing acute maternal T. gondii infection. This is a clearly reasonable approach. In such cases, Montoya and Remington recommend fetal ultrasound as soon as possible and amniotic fluid PCR at 18 weeks' gestation to determine fetal infection. If maternal infection was diagnosed before 18 weeks' gestation, most experts in the US recommend treatment begin with spiramycin until PCR and ultrasound results are available. Then, if either is positive, treatment switches to pyramethamine sulfadiazine and folinic acid (though others question its superiority to spiramycin for this or any indication); if negative, [16, 33, 34] , spiramycin should be started or continued. If instead maternal infection is diagnosed after 18 weeks' gestation, pyramethamine sulfadiazine and folinic acid are the default treatment until and unless PCR and ultrasound are negative, in which case either pyramethamine sulfadiazine with folinic acid or spiramycin can be continued until delivery.
The efficacy of spiramycin, which most providers reported not knowing, is uncertain; comparisons with historical controls suggest benefit [35] [36] [37] while more recent nonrandomized studies [38] suggest it may decrease sequelae only [39, 40] . With a confirmed diagnosis of acute T. gondii infection from the Palo Alto Research Institute, spiramycin is available in the United States through the FDA Division of Special Pathogen and Immunologic Drug Products under an Investigational New Drug license, at 301-796-0563, -1400, or -0706.
The higher prevalence of seroscreening asymptomatic pregnant women among providers in the US Northeast is consistent with an increased prevalence of toxoplasmosis exposure in this region [41] (29.2, vs. 22.5 % nationally in 1988-1994).
Limitations of our study include the use of self-reported data and the low survey response rates, all potentially causing overestimation of practitioner knowledge. The many comparisons between CARN and non-CARN respondents may have caused discovery of spurious differences. The Clopper-Pearson method may not fully account for any intracluster correlation within the provider groups in which survey recipients were selected, but given the method used for composing these groups, intracluster correlation should be minimal, with any resulting underestimation of variance also countered using sandwich estimators for variance.
Continuing education for providers on T. gondii prevention, diagnosis, and treatment is needed. Updated ACOG guidelines addressing these issues would be of particular benefit. However, additional evidence is needed on the magnitudes of expected benefits, harms and costs of routine screening, and comparative effectiveness of alternative antimicrobial regimens against maternal-fetal transmission and sequellae.
